REACH: Medication Assistance Program
Individual results may vary. Xenazine may not be effective in reducing choreic movements in all HD patients. Please review the Important Safety Information, including Boxed Warning about the increased risk of depression and suicidality, below.
Chorea Symptoms in Huntington's Disease
Dr. Sung discusses how chorea can affect Huntington's disease patients.
Considering Xenazine for Huntington’s Disease Chorea Symptoms
Learn more about Xenazine and how it may help with HD chorea symptoms.
Matt’s HD Chorea
See how Matt and his caregiver and wife, Karen, worked to find treatment options, including Xenazine, to help manage his HD chorea.
Medication Assistance Program: REACH
Learn about Lundbeck’s medication assistance program, REACH, which offers financial assistance for Xenazine patients who qualify.
REACH (which stands for Resources, Education and Access for patients with Chorea associated with Huntington’s disease) is a comprehensive assistance program designed to help patients who may benefit from Xenazine® (tetrabenazine) therapy manage their medication costs, if they qualify, and get their Xenazine prescriptions.
If you have questions concerning your ability to pay for your Xenazine prescription, you can call the Xenazine Information Center (XIC) at 1-888-882-6013. In some cases, the XIC will also call you if they need additional information related to your prescription.
Depending upon your or your loved one’s insurance coverage and financial need, REACH offers a variety of services:
Xenazine Information Center (XIC)
A dedicated team is available to help patients, caregivers and physicians through the prescription process.
Assistance with free medication is available for eligible or qualified patients with demonstrated financial need. The XIC will determine if you qualify.
Patient Starter Rx (prescription supply)*
Patients may receive their first Xenazine prescription within five days after the physician’s office faxes in a completed prescription form.
Qualified patients may receive assistance with their co-pay or co-insurance. The XIC will determine if you qualify. Currently, 85 percent of U.S. patients taking Xenazine have a monthly co-pay of $50 or less before requesting co-pay assistance**. If patients take the further step of applying for assistance, their out-of-pocket cost may potentially drop to $0.
*Program not available in all states.
**As of June 2012.